ArQule, Inc. (ARQL)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paolo Pucci
Employees:
36
ONE WALL STREET, BURLINGTON, MA 01803
781-994-0300

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its proprietary pipeline is directed towards molecular targets and biological processes with demonstrated roles in the development of human cancers. Its portfolio includes Tivantinib, ARQ 087, ARQ 092, ARQ 761, and ARQ 751. The company was founded in 1993 and is headquartered in Burlington, MA.

Data derived from most recent annual or quarterly report
Market Cap 2.405 Billion Shares Outstanding120.26 Million Avg 30-day Volume 4.217 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.26
Price to Revenue181.2902 Debt to Equity0.0952 EBITDA-38.294 Million
Price to Book Value5.6533 Operating Margin-828.1257 Enterprise Value706.13 Million
Current Ratio8.272 EPS Growth-1.188 Quick Ratio8.146
1 Yr BETA 0.5572 52-week High/Low 0.0 / Profit Margin-808.0628
Operating Cash Flow Growth-136.071 Altman Z-Score14.6482 Free Cash Flow to Firm -24.585 Million
View SEC Filings from ARQL instead.

View recent insider trading info

Funds Holding ARQL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ARQL BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2020-01-16:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-12-17:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-12-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-10-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-08-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-06-25:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-05-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-04-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2019-03-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-10-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ZENNER PATRICK J

    • Director
    No longer subject to file 2020-01-16 0

    LOBERG MICHAEL D

    • Director
    No longer subject to file 2020-01-16 0

    BARABE TIMOTHY C

    • Director
    No longer subject to file 2020-01-16 0

    LINDSAY RONALD M

    • Director
    No longer subject to file 2020-01-16 0

    MESSENGER WILLIAM G

    • Director
    No longer subject to file 2020-01-16 0

    LAWRENCE PETER S PRESIDENT AND COO

    • Officer
    No longer subject to file 2020-01-16 0

    SCHWARTZ BRIAN SEE REMARKS

    • Officer
    No longer subject to file 2020-01-16 0

    PUCCI PAOLO CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    No longer subject to file 2020-01-16 0

    KELLEY SUSAN L.

    • Director
    No longer subject to file 2020-01-16 0

    NUSSBAUM RAN

    • Director
    No longer subject to file 2020-01-16 0

    SCHAMBER BLAINE VP FINANCE, CAO

    • Officer
    No longer subject to file 2020-01-16 0

    SCHEGERIN MARC CFO AND TREASURER

    • Officer
    No longer subject to file 2020-01-16 0

    MERCK & CO., INC.

    MERCK SHARP & DOHME CORP.

    0 2019-12-06 0

    WEISKOPF ROBERT J CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-03-12 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    771,305 2018-05-30 0

    CHAN THOMAS C K CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2012-02-01 0

    SIMONIAN NANCY A

    • Director
    0 2010-05-13 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • DIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNER
    No longer subject to file 2010-04-05 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INVESTMENTS LLC

    BVF INC/IL

    • 10% Owner
    • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
    12,244,073 2008-11-21 0

    RULEWSKI NIGEL J FORMER CHIEF MEDICAL OFFICER

    • Officer
    0 2008-07-22 0

    HILL STEPHEN A PRESIDENT AND CEO

    • Officer
    • Director
    965,000 2007-10-04 0

    LI CHIANG J EVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    293,125 2007-01-26 0

    WOODRICH RICHARD H ACTING CHIEF FINANCIAL OFFICER

    • Officer
    100 2006-09-01 0

    ASTRUE MICHAEL J

    • Director
    25,000 2006-05-18 0

    HA NGOC TUAN

    • Director
    43,000 2006-05-18 0

    MAWHINNEY LOUISE VP AND CHIEF FINANCIAL OFFICER

    • Officer
    155,000 2006-01-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments